Methods and Compositions for Treating or Preventing Symptoms of Hormonal Variations
OwnerGeorge E. Royster, JR.inventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods, compositions, and kits for treating or preventing symptoms of hormonal variation. The method comprises the steps of administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations. The receptor antagonist binds to at least one receptor selected from a serotonin type 2A (5-HT.sub.2A) and/or a dopamine type 2 (D.sub.2) receptors.
Claims29
A method for treatment or prevention of symptoms of hormonal variation, comprising:
- identifying a subject having one or more symptoms of hormonal variations;
- and
- administering an effective amount of a receptor antagonist to the subject, wherein the receptor antagonist binds to at least one selected from a serotonin type 2A (5-HT.sub.2A) receptor and a dopamine type 2 (D.sub.2) receptor.
A method for treatment or prevention of symptoms of hormonal variation, comprising:
- identifying a subject having one or more symptoms of hormonal variations;
- and
- administering an effective amount of a receptor antagonist and another compound known to reduce or prevent the symptoms of hormonal variation to the subject, wherein the receptor antagonist binds to at least one selected from a serotonin type 2A (5-HT.sub.2A) receptor and a dopamine type 2 (D.sub.2) receptor.
A pharmaceutical composition for treatment or prevention of symptoms of hormonal variation, comprising:
- an effective amount of a receptor antagonist in a pharmaceutically acceptable carrier, said receptor antagonist being of the type that binds to at least one receptor of a serotonin type 2A (5-HT.sub.2A) receptor and/or a dopamine type 2 (D.sub.2) receptor;
- and
- wherein the receptor antagonist is used to treat or prevent symptoms of hormonal variation.
A kit for treatment or prevention of symptoms of hormonal variation, comprising:
- an effective amount of a receptor antagonist in a pharmaceutically acceptable carrier, said receptor antagonist being of the type that binds to at least one receptor of a serotonin type 2A (5-HT.sub.2A) receptor and/or a dopamine type 2 (D.sub.2) receptor;
- and
- instructions for performing at least one method of the invention.
Dependencies are inferred from the claim text.